Conshohocken, PA, September 11, 2023 (Globe Newswire) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical enterprise dedicated to pioneering novel therapies for nonalcoholic steatohepatitis (NASH), has officially introduced Bill Sibold as the incoming Chief Executive Officer (CEO). Bill Sibold, a distinguished leader, has also assumed a position on Madrigal's esteemed Board of Directors.
Read full article here.
Rahway, NJ & Cambridge, MA, November 21, 2023 (Business Wire) -- Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, and Caraway Therapeutics, Inc. declare a definitive agr
Zürich, Switzerland, November 16, 2023 (Business Wire) -- Memo Therapeutics AG (“MTx”), a late-stage biotech firm advancing top-tier therapeutic antibodies, discloses the appointment of Erik van den
Marlborough, MA, November 17, 2023 (PRNewswire) -- Boston Scientific Corporation (NYSE: BSX) announces the completion of its acquisition of Relievant Medsystems Inc., the sole provider of the FDA-cl
